BioCardia Analyst Ratings
BioCardia Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/10/2023 | 890.53% | HC Wainwright & Co. | → $9 | Reiterates | Buy → Buy |
| 07/24/2023 | 890.53% | HC Wainwright & Co. | $9 → $9 | Reiterates | Buy → Buy |
| 06/21/2023 | 890.53% | HC Wainwright & Co. | → $9 | Reiterates | Buy → Buy |
| 05/11/2023 | 890.53% | HC Wainwright & Co. | → $9 | Reiterates | Buy → Buy |
| 03/30/2023 | 890.53% | HC Wainwright & Co. | → $9 | Reiterates | → Buy |
| 11/11/2022 | — | Dawson James | Downgrades | Buy → Neutral | |
| 12/20/2021 | 890.53% | HC Wainwright & Co. | → $9 | Initiates Coverage On | → Buy |
| 04/16/2021 | — | Dawson James | Downgrades | Buy → Neutral | |
| 09/21/2020 | 1165.68% | Alliance Global Partners | → $11.5 | Initiates Coverage On | → Buy |
| 11/26/2019 | 2321.31% | Brookline Capital | → $22 | Initiates Coverage On | → Buy |
| 10/10/2019 | 890.53% | Maxim Group | → $9 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 2023年08月10日 | 890.53% | HC Wainwright公司 | →$9 | 重申 | 購買→購買 |
| 07/24/2023 | 890.53% | HC Wainwright公司 | $9→$9 | 重申 | 購買→購買 |
| 2023年6月21日 | 890.53% | HC Wainwright公司 | →$9 | 重申 | 購買→購買 |
| 2023年05月11日 | 890.53% | HC Wainwright公司 | →$9 | 重申 | 購買→購買 |
| 03/30/2023 | 890.53% | HC Wainwright公司 | →$9 | 重申 | →購買 |
| 2022年11月11日 | - | 道森·詹姆斯 | 評級下調 | 購買→中性 | |
| 12/20/2021 | 890.53% | HC Wainwright公司 | →$9 | 開始承保 | →購買 |
| 04/16/2021 | - | 道森·詹姆斯 | 評級下調 | 購買→中性 | |
| 2020/09/21 | 1165.68% | 聯盟全球合作夥伴 | →$11.5 | 開始承保 | →購買 |
| 2019年11月26日 | 2321.31% | 布魯克林資本 | →$22 | 開始承保 | →購買 |
| 2019年10月10日 | 890.53% | Maxim集團 | →$9 | 開始承保 | →購買 |
What is the target price for BioCardia (BCDA)?
BioCardia(BCDA)的目標價格是多少？
The latest price target for BioCardia (NASDAQ: BCDA) was reported by HC Wainwright & Co. on August 10, 2023. The analyst firm set a price target for $9.00 expecting BCDA to rise to within 12 months (a possible 890.53% upside). 6 analyst firms have reported ratings in the last year.
納斯達克(BCDA)的最新目標價是由HC Wainwright&Co.於2023年8月10日報道的。這家分析公司將目標價定為9美元，預計BCDA將在12個月內上漲至(可能上漲890.53%)。6家分析公司在過去一年公佈了評級。
What is the most recent analyst rating for BioCardia (BCDA)?
最近分析師對BioCardia(BCDA)的評級是多少？
The latest analyst rating for BioCardia (NASDAQ: BCDA) was provided by HC Wainwright & Co., and BioCardia reiterated their buy rating.
分析師對百佳(納斯達克代碼：BCDA)的最新評級由HC Wainwright&Co.提供，百佳重申其買入評級。
When is the next analyst rating going to be posted or updated for BioCardia (BCDA)?
BioCardia(BCDA)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of BioCardia, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for BioCardia was filed on August 10, 2023 so you should expect the next rating to be made available sometime around August 10, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括查閱公共財務報表，與BioCardia的高管和客戶交談，以及收聽收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。BioCardia的上一次評級是在2023年8月10日提交的，所以你應該預計下一次評級將在2024年8月10日左右提供。
Is the Analyst Rating BioCardia (BCDA) correct?
分析師對BioCardia(BCDA)的評級正確嗎？
While ratings are subjective and will change, the latest BioCardia (BCDA) rating was a reiterated with a price target of $0.00 to $9.00. The current price BioCardia (BCDA) is trading at is $0.91, which is within the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的BioCardia(BCDA)評級被重申，目標價在0.00美元至9.00美元之間。BioCardia(BCDA)目前的交易價格為0.91美元，在分析師的預測範圍內。